| Carmelo Graffagnino, MD | |
|
2100 Erwin Road, Durham, NC 27710-0001 | |
| (919) 684-8111 | |
| Not Available |
| Full Name | Carmelo Graffagnino |
|---|---|
| Gender | Male |
| Speciality | Neurology |
| Experience | 39 Years |
| Location | 2100 Erwin Road, Durham, North Carolina |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1043394950 | NPI | - | NPPES |
| 8936539 | Medicaid | NC |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2084N0400X | Psychiatry & Neurology - Neurology | 34981 (North Carolina) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Duke University Hospital | Durham, NC | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Duke Health Integrated Practice Inc | 8325412737 | 2551 |
News Archive
Inspire Pharmaceuticals, Inc. announced today that data will be presented on denufosol tetrasodium, an investigational therapy for cystic fibrosis (CF), during oral and poster presentations at the European Respiratory Society (ERS) Annual Congress September 18 - 22, 2010 in Barcelona, Spain.
Actifio, the Protection and Availability Storage (PAS) platform company, today announced results of its deployment at Boston University Medical Campus (BUMC) where it helped to gain control over its diverse, heterogeneous IT infrastructure.
During the 63rd U.N. Department of Public Information/NGO Conference on Monday in Melbourne, Australia, U.N. Secretary-General Ban Ki-moon "call[ed] on delegates to do more to save the lives of mothers and babies," the Australian Associated Press/Sydney Morning Herald reports (Alexander/Rose, 8/30).
Depomed, Inc. today announced that its licensee has submitted a New Drug Application (NDA) for DM-1796 to the U.S. Food and Drug Administration (FDA) for the management of postherpetic neuralgia (PHN), or pain after shingles. DM-1796 is an investigational, extended release, once-daily tablet formulation of gabapentin designed to reduce dosing frequency and have a low incidence of side effects.
› Verified 5 days ago
| Entity Name | Private Diagnostic Clinic Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1457389033 PECOS PAC ID: 1355254368 Enrollment ID: O20031204000577 |
News Archive
Inspire Pharmaceuticals, Inc. announced today that data will be presented on denufosol tetrasodium, an investigational therapy for cystic fibrosis (CF), during oral and poster presentations at the European Respiratory Society (ERS) Annual Congress September 18 - 22, 2010 in Barcelona, Spain.
Actifio, the Protection and Availability Storage (PAS) platform company, today announced results of its deployment at Boston University Medical Campus (BUMC) where it helped to gain control over its diverse, heterogeneous IT infrastructure.
During the 63rd U.N. Department of Public Information/NGO Conference on Monday in Melbourne, Australia, U.N. Secretary-General Ban Ki-moon "call[ed] on delegates to do more to save the lives of mothers and babies," the Australian Associated Press/Sydney Morning Herald reports (Alexander/Rose, 8/30).
Depomed, Inc. today announced that its licensee has submitted a New Drug Application (NDA) for DM-1796 to the U.S. Food and Drug Administration (FDA) for the management of postherpetic neuralgia (PHN), or pain after shingles. DM-1796 is an investigational, extended release, once-daily tablet formulation of gabapentin designed to reduce dosing frequency and have a low incidence of side effects.
› Verified 5 days ago
| Entity Name | Duke Health Integrated Practice Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1205553369 PECOS PAC ID: 8325412737 Enrollment ID: O20230327002247 |
News Archive
Inspire Pharmaceuticals, Inc. announced today that data will be presented on denufosol tetrasodium, an investigational therapy for cystic fibrosis (CF), during oral and poster presentations at the European Respiratory Society (ERS) Annual Congress September 18 - 22, 2010 in Barcelona, Spain.
Actifio, the Protection and Availability Storage (PAS) platform company, today announced results of its deployment at Boston University Medical Campus (BUMC) where it helped to gain control over its diverse, heterogeneous IT infrastructure.
During the 63rd U.N. Department of Public Information/NGO Conference on Monday in Melbourne, Australia, U.N. Secretary-General Ban Ki-moon "call[ed] on delegates to do more to save the lives of mothers and babies," the Australian Associated Press/Sydney Morning Herald reports (Alexander/Rose, 8/30).
Depomed, Inc. today announced that its licensee has submitted a New Drug Application (NDA) for DM-1796 to the U.S. Food and Drug Administration (FDA) for the management of postherpetic neuralgia (PHN), or pain after shingles. DM-1796 is an investigational, extended release, once-daily tablet formulation of gabapentin designed to reduce dosing frequency and have a low incidence of side effects.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Carmelo Graffagnino, MD 5213 S. Alston Avenue, Durham, NC 27713-4430 Ph: (919) 620-4915 | Carmelo Graffagnino, MD 2100 Erwin Road, Durham, NC 27710-0001 Ph: (919) 684-8111 |
News Archive
Inspire Pharmaceuticals, Inc. announced today that data will be presented on denufosol tetrasodium, an investigational therapy for cystic fibrosis (CF), during oral and poster presentations at the European Respiratory Society (ERS) Annual Congress September 18 - 22, 2010 in Barcelona, Spain.
Actifio, the Protection and Availability Storage (PAS) platform company, today announced results of its deployment at Boston University Medical Campus (BUMC) where it helped to gain control over its diverse, heterogeneous IT infrastructure.
During the 63rd U.N. Department of Public Information/NGO Conference on Monday in Melbourne, Australia, U.N. Secretary-General Ban Ki-moon "call[ed] on delegates to do more to save the lives of mothers and babies," the Australian Associated Press/Sydney Morning Herald reports (Alexander/Rose, 8/30).
Depomed, Inc. today announced that its licensee has submitted a New Drug Application (NDA) for DM-1796 to the U.S. Food and Drug Administration (FDA) for the management of postherpetic neuralgia (PHN), or pain after shingles. DM-1796 is an investigational, extended release, once-daily tablet formulation of gabapentin designed to reduce dosing frequency and have a low incidence of side effects.
› Verified 5 days ago
Christopher Eckstein, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 40 Duke Medicine Cir, Durham, NC 27710 Phone: 919-684-8111 | |
Dr. Yuriy Zeylikman, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 2301 Erwin Rd, Durham, NC 27705 Phone: 919-684-8111 | |
Dr. James O. Mcnamara, M.D. Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: Dumc 3209, Durham, NC 27710 Phone: 919-684-4241 | |
Dr. June P Vanbruggen, MD Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 3239 Winfield Dr, Durham, NC 27707 Phone: 919-489-2617 Fax: 919-489-7037 | |
Dr. Kevin A Kahn, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 6114 Fayetteville Rd Ste 109, Durham, NC 27713 Phone: 919-942-4424 Fax: 919-942-4440 | |
Dr. Holly B. Rogers, MD Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: Duke University, 214 Page Bldg, Durham, NC 27708 Phone: 919-660-1000 Fax: 919-660-1024 | |
Dr. Sally You, DO Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 2301 Erwin Rd, Durham, NC 27705 Phone: 919-684-8111 |